Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Common Equity data on record, last reported at -$12.0 million in Q3 2025.

  • For Q3 2025, Common Equity fell 307.32% year-over-year to -$12.0 million; the TTM value through Sep 2025 reached -$12.0 million, down 307.32%, while the annual FY2024 figure was $2.0 million, 92.17% down from the prior year.
  • Common Equity reached -$12.0 million in Q3 2025 per RANI's latest filing, down from -$9.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $131.7 million in Q3 2021 and bottomed at -$123.7 million in Q2 2021.
  • Average Common Equity over 5 years is $29.1 million, with a median of $25.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 207.26% in 2021, then tumbled 307.32% in 2025.
  • A 5-year view of Common Equity shows it stood at $121.6 million in 2021, then tumbled by 39.12% to $74.0 million in 2022, then tumbled by 65.62% to $25.4 million in 2023, then tumbled by 92.17% to $2.0 million in 2024, then plummeted by 701.05% to -$12.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$12.0 million in Q3 2025, -$9.2 million in Q2 2025, and -$5.3 million in Q1 2025.